Form 8-K - Current report:
SEC Accession No. 0001193125-25-113811
Filing Date
2025-05-06
Accepted
2025-05-06 16:05:20
Documents
15
Period of Report
2025-05-05
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d905721d8k.htm   iXBRL 8-K 23888
2 EX-99.1 d905721dex991.htm EX-99.1 12059
6 GRAPHIC g905721g0506232330417.jpg GRAPHIC 1966
  Complete submission text file 0001193125-25-113811.txt   162023

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atra-20250505.xsd EX-101.SCH 2853
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20250505_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20250505_pre.xml EX-101.PRE 10814
17 EXTRACTED XBRL INSTANCE DOCUMENT d905721d8k_htm.xml XML 3515
Mailing Address 1280 RANCHO CONEJO BLVD THOUSAND OAKS CA 91320
Business Address 1280 RANCHO CONEJO BLVD THOUSAND OAKS CA 91320 805-623-4211
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

EIN.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 25917186
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)